Summary: Assessment of the extent of bioavailability (EBA) of salmon calcitonin (sCT) from hypocalcemic eŠects after intranasal administration was presented in rats. An integrated pharmacokineticpharmacodynamic (PK-PD) model with the endogenous Ca regulation system was applied. The in‰uence of camostat mesilate, a protease inhibitor, on absorption of sCT was also estimated. Camostat, coadministered intravascularly, delayed the elimination of sCT. Although the hypocalcemic eŠect of sCT after i.v. administration was accelerated when camostat was coadministered intravenously, the enhanced eŠect could not be expressed only by pharmacokinetic change of sCT, and then the pharmacological data in the presence of camostat were analyzed to obtain optimal PD parameters. For the absorption of sCT after i.n. administration, a saturable absorptive process and a zero-order kinetic clearance from the nasal cavity were introduced to the model. The regression curvesˆtted the observed data, and camostat caused both an increase in maximum absorption rate and a decrease in the clearance parameter compared with the control. According to this modiˆed PK-PD relationship, plasma sCT concentrations following i.n. administration of sCT with camostat were predicted well using its pharmacological eŠects. The EBA of sCT calculated from the simulated concentrations increased more than 4-folds compared with the control study. These results indicate the potential for prediction of plasma sCT concentration from the hypocalcemic eŠect.
Introduction
The intranasal absorption of salmon calcitonin (sCT) coadministered with camostat mesilate, a synthetic protease inhibitor, has been evaluated to characterize the enzymatic barrier of the nasal mucosa. 1) An assessment of the bioavailability was made using the``pharmacological availability (PA)'' which was calculated from the hypocalcemic eŠect, as a substitute of the extent of bioavailability. However, there is no conclusive proof that plasma concentrations are always proportional to the pharmacological eŠects, and the use of PA in evaluating drug formulations might lead to erroneous conclusions.
2) Therefore, the concentration of sCT must be determined practically for the accurate assessment of bioavailability, though the available analytical method of sCT lacks adequate sensitivity for the determination of low plasma concentrations especially after intranasal administration.
In the precedent report, 3) we quantiˆed the pharmacokinetic-pharmacodynamic (PK-PD) relationship after i.v. bolus administration of sCT in rats. The result indicated the potential for predicting of plasma sCT concentrations from the hypocalcemic eŠect using a PK-PD model (Fig. 1) . Brie‰y, the model consists of the hypocalcemic eŠect of sCT and the endogenous Ca regulation system associated with rat CT (rCT). A pharmacokinetic equation for sCT with a two-compart- The pharmacokinetics is linked to the Ca regulation system (gray area) through the pharmacodynamic model. sCT 1 and sCT 2 : amounts of sCT in the central and peripheral compartment; K 0 : the infusion rate; k 12 , k 21 and k 10 :ˆrst-order constants; V: the distribution volume of the central compartment; sCT 1C : plasma sCT concentrations; Ca: plasma Ca concentrations; rCT, rCT 1 and rCT 2 : rCT concentrations in the plasma and the eŠect compartments; k Ca10 and k rCT10 : theˆrst-order kinetic constants for the Ca and rCT; t rCT ; theˆrst-order kinetic constant for the eŠect compartments of rCT; a: the exponential function (＝q 1 ･e q2･Ca ); F 1 and F 2 ; proportional constants for the secretion of rCT; b: the proportional constant for the eŠect of rCT on the plasma Ca level; E 1 and E 2 ; amounts of sCT in the eŠect compartments: t sCT ; theˆrst-order kinetic constant; g: the E max model equation (＝(E max ･E 2 ) W (1 W Q＋E 2 )); E max : the maximum eŠect of sCT: 1 W Q; the a‹nity constant of sCT to the receptor (see Ref.
3). ment model was linked to an E max model as suppression of plasma Ca generation through two eŠect compartments. The rCT, expressed by a one-compartment pharmacokinetic model, eŠects linearly suppression of plasma Ca concentration, however the generation of plasma rCT is also involved in the Ca level exponentially.
The objective of this study was to propose a method of evaluating the bioavailability of sCT through plasma concentrations predicted from the hypocalcemic eŠect using the PK-PD model. As a model study, the previous results after i.n. administration of sCT with or without camostat mesilate 1) was reanalyzed.
Materials and Methods
Chemicals: Synthesized salmon calcitonin (sCT) was kindly supplied by Teikoku Hormone Mfg. Co. (Tokyo, Japan). Camostat mesilate (FOY-305) was supplied by Ono Pharm. Co., Ltd. (Osaka, Japan). Bovine serum albumin (BSA) was purchased from Sigma Chemical Co. (St. Louis, MO). Saline was obtained from Otsuka Pharmaceuticals (Tokyo, Japan). All other reagents and solvents were commercial products of reagent grade (Wako Pure Chemical Industries, Osaka, Japan).
Animal surgery: Male Wistar rats (Japan SLC Inc., Shizuoka, Japan), weighing 200 to 240 g, were used. The rats were housed in environmentally regulated facilities (temperature: 24±19 C, humidity: 55±10z), exposed to alternative 12 hr cycles (6:00 and 18:00) of light and dark for over 1 week, and allowed free access to a standard diet and tap water. The cannulas inserted into the femoral artery, femoral vein and jugular vein of each animal were exteriorized via the neck, as reported previously.
3) After surgery, the animals were left at least 15 hrs under fasting to recover. All of these methods had previously been approved by the Animal Experimentation Committee of Osaka University of Pharmaceutical Sciences.
Administration: On the day of the experiment, the rats were housed in individual metabolic cages. sCT was dissolved in saline containing 0.1z BSA. Camostat mesilate was dissolved in the sCT solution at 5 mmol W L (dose: 0.5 mmol W rat). In the bolus administration study to assess the pharmacological eŠect, the sCT preparation was injected into the femoral veins via the catheters at doses ranging from 0.075 to 0.225 IU W kg. In the preliminary PK study, we found that the elimination of sCT after i.v. bolus administration is too fast to be determined precisely.
1) Then, sCT was injected continuously (5 IU W kg W hr) for 75 min into the femoral artery with an infusion pump (STS-523: Terumo corporation, Tokyo, Japan). Blood samples were withdrawn from the femoral vein predose (blank plasma), and at designated postdose intervals. Plasma sCT and Ca concentrations were determined as described previously.
3) The i.n. administration study was demonstrated in the previous paper.
1)
Data analysis: The concentration-time data was analyzed by a nonlinear regression program, FKDM 4) using a Micro VAX II computer (DEC, Maynard, MS) or a personal computer (NEC Corporation, Tokyo, Japan). The diŠerential equations were solved by the Runge-Kutta-Gill method. The areas under the concentration-time curve (AUC) following administration of sCT, from 0 to 5 hr, were calculated by the linear trapezoidal method. The extent of bioavailability (F) was calculated by the following equation:
where Di.n. and Di.v. are the intranasal and intravenous doses of sCT, respectively.
Results
Extent of bioavailability after i.n. administration of sCT: The time course of plasma Ca concentrations after i.n. administration of sCT (10 IU W kg) without camostat mesilate was shown in Fig. 2A (plotted points). Compared with the control group, a signiˆcant hypocalcemic eŠect was observed. To explain a pharmacokinetic property of the nasal absorption, we introduced an absorption process to the previous PK-PD model 3) as shown in Fig. 1 . In the modeling, we assumed as follows; a) the plasma Ca is generated by a zero-order kinetic process (KCa0), and eliminated by â rst-order kinetic process. b) The rCT is secreted in accordance with the plasma Ca concentration by an exponential function. c) If plasma Ca level is above the normal level, rCT aŠects the bone resorption to maintain the normal level of plasma Ca in a feedback manner. d) The rCT exerts its pharmacological eŠect via an additional eŠect compartment.
3) In the i.n. administration study, we assumed that sCT is absorbed from the nasal mucosa according to the Michaelis-Menten type kinetics and that sCT is eliminated from the nasal cavity by a zero-order kinetic process. The diŠerential equations of the amount of sCT in the nasal cavity are,
and the following equation 4b is substituted for Eq. 4 in the previous paper.
3) dsCT1 dt ＝k a ･sCT n -(k 12 ＋k 10 )･sCT1＋k21･sCT2
Eq. 4b
Where ka＝ Vmax Km＋sCTn Eq. 4c
Vmax and Km are the maximum rate of absorption and the Michaelis constant, respectively. Kn0 is the zeroorder constant and sCTn is the amount of sCT in the nasal cavity. The solid line, shown in Fig. 2A , represents the response curve obtained byˆtting the PK-PD model to the observed data. All of the pharmacokinetic, pharmacodynamic and physiological parameters, except absorption parameters, were identical with the previous report. The estimated absorption parameters are listed in Table 1 . The solid line shown in Fig. 2B represents the model-predicted plasma sCT concentration, and reached a steady-state at about 6 mIU W mL over 0.5¿1.5 hrs after administration. AUC was calculated and, thus, the extent of bioavailability (F) was estimated, as shown in Table 1 . Although a signiˆcant hypocalcemic eŠect was observed after i.n. administration of sCT, extremely low bioavailability (0.87z) was indicated.
EŠects of camostat mesilate on the extent of bioavailability of sCT: The eŠect of camostat mesilate on the pharmacokinetics of sCT was investigated. The sCT (5 IU W kg W hr) solution, including 0.5 mmol W rat camostat mesilate, was infused for 75 min, and plasma sCT concentrations were determined ( Fig. 3A; plotted points). Then these observed plasma concentration data wereˆtted to a two-compartment open model. The solid line shown in Fig. 3A represents the result of the least-squares regressionˆtting and the estimated PK parameters are listed in Table 2 . The distribution volumes Vc and Vt were signiˆcantly in‰uenced by camostat mesilate. Figure 3B shows the model-predicted sCT concentration in plasma after i.v. bolus administration with camostat mesilate. Camostat mesilate deceased the elimination of sCT. Using these PK parameters, the hypocalcemic eŠect following i.v. bolus administration with camostat mesilate (0.5 mmol W rat) was predicted; however, the predicted curves did not describe the observed data (data not shown). This result indicates that camostat mesilate in‰uenced not only PK of sCT but also pharmacological processes of sCT. In order to reveal the eŠect of camostat mesilate on the pharmacodynamics of sCT, plasma Ca concentrations after i.v. coadministration of camostat mesilate wereˆtted to the PK-PD model (Fig. 4) . The solid lines shown in Fig. 4 represent the theoretical values, and the estimated PD parameters are listed in Table 2 . The regression curvesˆtted the observed data well. As shown in Table 2 , the Emax and 1 W Q increased 2-fold to 4-fold with camostat coadministration, indicating that these changes may account for prolongation and enhancement in the pharmacological eŠect of sCT by camostat mesilate.
The plotted points shown in Fig. 2A represent the changes in plasma Ca levels following i.n. administration of sCT (10 IU W kg) with camostat mesilate (0.1 and 1 mmol W rat), which were reported by Morimoto et al.
1)
The hypocalcemic eŠect was increased and prolonged as doses of camostat mesilate increased. To elucidate the in‰uence of camostat mesilate on the absorption of sCT from the nasal mucosa, the pharmacological data were analyzed by the modiˆed PK-PD model, using identical PK and PD parameter values for camostat coadministration shown in Table 2 . The solid lines shown in Fig. 2A traced the observed data well. This indicates that the modiˆed PK-PD model explains the PK-PD relationship after i.n. administration of sCT with camostat mesilate. The estimated absorption parameters were summarized in Table 1 . Because the estimated Km value was almost identical with the control study (Fig. 2) , the Km value wasˆxed to the control value (1.17 mIU). The estimated values of Vmax were increased while the K n0 values were decreased; however, these changes were depend on the doses of camostat mesilate.
Prediction of bioavailability after i.n. administration of sCT with camostat mesilate: Figure 2B represents the predicted plasma sCT concentrations after i.n. administration of sCT (10 IU W kg) in the presence of camostat mesilate. The solid lines show the concentration-time proˆles after coadministration of camostat mesilate (0.1 and 1 mmol W rat) and the dashed line shows the proˆle after administration of sCT alone. As doses of camostat mesilate increased, the maximum levels of sCT were markedly enhanced and high plasma levels were prolonged. Then, AUC and the extent of bioavailability (F) were calculated and summarized in Table 1 . Compared with the control, F increased more than 4-folds with camostat mesilate coadministration.
Discussion
Application of PK-PD model to the i.n. administration study: In order to elucidate the applicability of the PK-PD model of sCT, the hypocalcemic eŠect versus time data following i.n. administration was analyzed. In the present model, we assumed that the absorption process of sCT from the nasal mucosa conforms to the Michaelis-Menten type kinetics, because a linear absorptive model could not explain the observed data (data not shown). The non-linear model is often used to represent a saturable ‰ux of substrates. The endocytotic transport of CT and elcatonin, a calcitonin derivative, from the nasal mucosa was reported. 5, 6) Although, this process may be related to, in part, the saturable absorption observed in the present study, the estimated parameter values are an outcome of general eŠect related to various factors associated with the absorption of sCT. As a result, the estimated value of Km was extermely low comparing with the administered dose and the absorptive proˆle showed an analog of the zero-order kinetics ( Table 1, Fig. 2B ). However, we applied the non-linear model to assess the eŠect of camostat mesilate, because there was not any evidence that the linearity of absorption is maintained in the presence of camostat mesilate. The elimination processes of sCT from the nasal cavity were integrated into a zero-order kinetic constant Kn0. Enzymatic degradation and mucociliary clearance may be included with this parameter.
1,7-9) Gonda and Gipps 10) demonstrated a mathematical model describing the rate processes for the disposition of drugs in the human nasal cavity. The model contained some parallel and sequential processes representing the drug transport by ‰uid ‰ow and mucociliary clearance, drug release and absorption, and so on. In our model, these respective processes were not expressed individually as diŠerent compartments. If an enzymatic hydrolysis rate and mucociliary clearance of sCT are determined separately, the absorption proˆle would be simulated more precisely.
Plasma sCT proˆles were predicted from the pharmacological data after i.n. administration of sCT. However, pharmacokinetic parameters of sCT were based on higher plasma concentrations compared with the predicted proˆle in the i.n. study. There have been no reports concerning the dose-relative pharmacokinetics of sCT at this range of doses, because disposition of sCT is extremely fast and sensitivity of assay method may be insu‹cient like our case. Even if a non-linear pharmacokinetics is presumed in our model, these model parameters can not be decide for lack of the observed concentrations of sCT.
EŠects of camostat mesilate on the PK-PD relationship of sCT: Intravascularlly administered camostat mesilate caused signiˆcant decrease in the distribution volume (Vc) of the central compartment for sCT, resulting in a delay of the disposition of sCT ( Table 2 , Fig. 3 ). In the previous report, 1) we demonstrated that camostat mesilate inhibits not only trypsin but leucine aminopeptidase (LAP) in nasal mucosa. Camostat mesilate also showed inhibitory eŠect to these proteases in plasma. It is known that trypsin and LAP distribute widely over various tissues and organs. Although camostat mesilate is quickly hydrolyzed by esterase in plasma, its metabolite, FOY-251, has inhibitory eŠect equal to the intact drug.
11) Therefore, change in the distribution volume may be involved in a wide inhibitory eŠect of camostat mesilate andW or its metabolite. This modiˆed pharmacokinetic property was also applied to explain plasma sCT concentrations after i.n. coadministration with camostat mesilate (Fig. 2B) . In order to in‰uence the pharmacokinetics of sCT, intranasally administered camostat mesilate has to be absorbed from nasal membrane and reach to blood ‰ow. In spite of poorer permeability of the intestinal mucosa comparing with the nasal mucosa, total excition of FOY-251 and main metabolite during 24 hrs in human urine was about 21z of the dose administered orally.
11) While, the estimated plasma Ca proˆle was quite diŠerent from the observed data, when the control set of PK and PD parameters was used to explain the results of i.n. study. Therefore, it is appropriate that we used the modiˆed PK parameters in relation to camostat mesilate in the analysis of i.n. study. However, camostat mesilate might be overdosed in the i.v. study judging from the intranasal permeability.
Plasma Ca levels after i.v. bolus coaministration of sCT and camostat mesilate could not be described well by the integrated model with the following set of PK, PD and physiological parameters: the PK parameters obtained in the presence of camostat mesilate, the PD parameters obtained in the absence of camostat mesilate and the physiological parameters of Ca regulation model. Then the pharmacological data was reanalyzed to estimate the optimal PD parameters. The physiological parameters for the Ca regulation system were used without any change because these parameters were unlikely to be aŠected by camostat mesilate. The estimated values of E max and 1 W Q were higher than those of the control condition without camostat mesilate. This eŠect of camostat mesilate is probably related with the inhibitory activity to enzymes such as trypsin in plasma and tissues. However, the actual mechanism is unclear and further investigation is needed.
Simulation of plasma sCT concentrations after i.n. administration of sCT with camostat mesilate: Hypocalcemic eŠects after i.n. administration of sCT with camostat mesilate could be well described using the PK-PD model with the Ca regulation system. Camostat mesilate also in‰uenced the nasal absorptive properties of sCT; causing an increase in the maximum absorption rate (Vmax) and a decrease in the nasal clearance (Kn0), depended on the dose of camostat mesilate. These facts clearly indicate that camostat mesilate protects sCT from hydrolysis of proteases. Furthermore, the change in these parameters might re‰ect an improvement of permeability caused by the functional alteration of the nasal mucosa associated with protease activities. The absolute bioavailabilities, calculated from modelpredicted plasma sCT concentrations, increased to 3.6¿4.9z from the control of 0.87z, when camostat mesilate was coadministered (at doses of 0.1¿1 mmol W rat). Sinswat and Tengamnuay 12) reported that bioavailability of sCT based on observed plasma concentrations was 1.22z after i.n. administration of sCT (10 IU W kg) in rats. This fact is consistent with our result, and the bioavailability estimated from the phar-macological eŠects of sCT using the PK-PD model is reasonable. In contrast, the PA of sCT, after i.n. administration of sCT with camostat mesilate, increased to 4.2¿5.1z from 3.16z (data not published), showing the possibility to overestimate bioavailabilities of sCT.
In conclusion, a method of assessing the extent of bioavailability of sCT from hypocalcemic data has been presented, and we demonstrates that the bioavailability is reasonably predicted using a PK-PD model. Furthermore, this result indicates that the pharmacological availability has a possibility overestimating the bioavailability of sCT. Thus, once PK and PD parameters are established for sCT and the endogenous Ca regulation system, the extent of bioavailability and plasma sCT proˆle will be easily and routinely predicted without determination of plasma sCT concentrations, for example, in a development phase of novel formulations.
